Everest Medicines Announces China NMPA Approval of CARDAMYST® for the Conversion of Acute Symptomatic Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm in Adults
China's NMPA has approved CARDAMYST (etripamil) nasal spray for converting acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults, marking Everest Medicines' first approved cardiovascular therapy in China. The approval was supported by the global pivotal Phase III RAPID trial and the China Phase III JX02002 study, both of which met their primary endpoints; in RAPID, 64% of patients who self-administered etripamil converted to sinus rhythm within 30 minutes versus 31% on placebo.
Key figures
- Drug Name
- CARDAMYST (etripamil)
- Phase Of Trial
- Phase III (global pivotal RAPID trial and China JX02002 study)
- Onset of effect
- as early as five minutes after administration
- Us fda approval
- December 2025
- Jx02002 hazard ratio
- 3.002
- Rapid conversion 30min
- 64% etripamil vs 31% placebo (HR = 2.62; p<0.001; N=99 vs N=85)
- China psvt patient population
- 3 to 6 million
- China combined patient potential
- more than 12 million including AFib-RVR
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.